Regulators take a growing interest in drug-makers’ moves to protect profits

Executives at drug company Actavis knew they had to move fast to avoid a plunge in sales of their top-selling drug, Namenda, a treatment for Alzheimer’s disease that would lose patent protection in July.Read full article >>





Read more ...